171 related articles for article (PubMed ID: 38520019)
1. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.
Luo F; Zhang M; Sun B; Xu C; Yang Y; Zhang Y; Li S; Chen G; Chen C; Li Y; Feng H
Mol Cancer; 2024 Mar; 23(1):60. PubMed ID: 38520019
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA LINC00115 promotes breast cancer metastasis by inhibiting miR-7.
Yuan C; Luo X; Duan S; Guo L
FEBS Open Bio; 2020 Jul; 10(7):1230-1237. PubMed ID: 32175684
[TBL] [Abstract][Full Text] [Related]
3. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity.
Tang J; Yu B; Li Y; Zhang W; Alvarez AA; Hu B; Cheng SY; Feng H
EMBO Rep; 2019 Dec; 20(12):e48170. PubMed ID: 31599491
[TBL] [Abstract][Full Text] [Related]
4. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
[TBL] [Abstract][Full Text] [Related]
5. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.
Lin A; Li C; Xing Z; Hu Q; Liang K; Han L; Wang C; Hawke DH; Wang S; Zhang Y; Wei Y; Ma G; Park PK; Zhou J; Zhou Y; Hu Z; Zhou Y; Marks JR; Liang H; Hung MC; Lin C; Yang L
Nat Cell Biol; 2016 Feb; 18(2):213-24. PubMed ID: 26751287
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
8. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
[TBL] [Abstract][Full Text] [Related]
9. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
10. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
[TBL] [Abstract][Full Text] [Related]
11. lncRNA LUCAT1/ELAVL1/LIN28B/SOX2 Positive Feedback Loop Promotes Cell Stemness in Triple-Negative Breast Cancer.
Xia L; Wang H
Breast J; 2022; 2022():7689718. PubMed ID: 35711895
[TBL] [Abstract][Full Text] [Related]
12. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Zhang H; Cai K; Wang J; Wang X; Cheng K; Shi F; Jiang L; Zhang Y; Dou J
Stem Cells; 2014 Nov; 32(11):2858-68. PubMed ID: 25070049
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X
J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
Chen J; Zhu M; Zou L; Xia J; Huang J; Deng Q; Xu R
Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):801-809. PubMed ID: 32632453
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
[TBL] [Abstract][Full Text] [Related]
18. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
19. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
